Literature DB >> 29323987

Care bundles in the management of a COPD exacerbation.

Charlotte Lloyd1, Joanne Garside2.   

Abstract

Chronic obstructive pulmonary disease (COPD), the umbrella term used to describe chronic lung diseases that cause limitations in lung airflow, is predicted to be the third leading cause of death by 2030. COPD is said to affect 3 million people in the UK, resulting in approximately 30 000 deaths each year. Related healthcare costs continue to escalate, not least because of increasing readmission rates associated with COPD emergencies. The use of care bundles to streamline care is becoming more popular in an attempt to tackle this issue. An integrative literature review was carried out to examine the effectiveness of the use of care bundles. The findings highlighted inconsistencies in the components of bundles, leading to inherent difficulties in assessing which specific component of the bundles led to positive outcomes. The results of this attempt to establish the effectiveness of care bundles in reducing readmission rates and quality of care were inconclusive. The authors recommend further research to investigate the individual components in the bundles and to introduce internationally agreed care bundles for the management of COPD.

Entities:  

Keywords:  COPD exacerbation; Care bundle; Effectiveness; Patient care; Readmission

Mesh:

Year:  2018        PMID: 29323987     DOI: 10.12968/bjon.2018.27.1.47

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  2 in total

1.  A Retrospective Study of Diaphragmatic Breathing Training Combined with Discharge Care Bundles in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Shuhui Yu; Chen Lu; Lingling Qin
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-14       Impact factor: 2.650

2.  Does pay-for-performance improve patient outcomes in acute exacerbation of COPD admissions?

Authors:  Philip W Stone; Alexander Adamson; John R Hurst; C Michael Roberts; Jennifer K Quint
Journal:  Thorax       Date:  2021-07-16       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.